Our study offers a fresh perspective on CRC prognosis and therapy, with implications that extend beyond SIGLEC1 itself to the broader field of cancer immunology and TCM-based anticancer therapies. The gene discussed is SIGLEC1; the disease is colorectal carcinoma.